Improving immune reconstitution while preventing graft-versus-host disease in allogeneic stem cell transplantation

Seminars in Hematology

Volumn 39, Issue 1, 2002, Pages 32-40

  Cavazzana Calvo, Marina ^a,b   André Schmutz, Isabelle ^a,b   Hacein Bey Abina, Salima ^a,b   Bensoussan, Danielle ^a,b   Le Deist, Françoise ^a,b   Fischer, Alain ^a,b  

^a HÔPITAL NECKER ENFANTS MALADES   (France)

^b UNIVERSITY HOSPITAL OF NANCY   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ALLOANTIGEN; B7 ANTIGEN; BUSULFAN; CD28 ANTIGEN; CD40 ANTIGEN; CD40 LIGAND; CD69 ANTIGEN; CD86 ANTIGEN; CYCLOPHOSPHAMIDE; CYTOTOXIC T LYMPHOCYTE ANTIGEN 4; INTERLEUKIN 2; INTERLEUKIN 2 RECEPTOR; THYMOCYTE ANTIBODY;

ALLOIMMUNITY; CLONAL ANERGY; GENE THERAPY; GRAFT VERSUS HOST REACTION; HUMAN; IMMUNE DEFICIENCY; IMMUNOSUPPRESSIVE TREATMENT; LEUKEMIA; LYMPHOCYTE DEPLETION; MOUSE; NONHUMAN; PRIORITY JOURNAL; RELAPSE; REVIEW; STEM CELL TRANSPLANTATION; SUICIDE GENE;

EID: 0036144582     PISSN: 00371963     EISSN: None     Source Type: Journal    
DOI: 10.1053/shem.2002.29251     Document Type: Article

References (80)

1. Treatment of high-risk acute leukemia with T-cell-depleted stem cells from related donors with one fully mismatched HLA haplotype
2. Bone marrow transplants from HLA-identical siblings as compared with chemotherapy for children with acute lymphoblastic leukemia in a second remission
3. Influence of severe combined immunodeficiency phenotype on the outcome of HLA non-identical, T-cell depleted bone marrow transplantation
4. Recent advances in graftversus-host disease (GVHD) prevention
5. + T cells tolerized ex vivo to host alloantigen by anti-CD40 ligand (CD40L: CD 154) antibody lose their graft-versus-host disease lethality capacity but retain nominal antigen responses
6. Co-blockade of the LFA 1:1CAM and CD28/CTLA4:B7 pathways is a highly effective means of preventing acute lethal graft-versus-host disease induced by fully major histocompatibility complex-disparate donor grafts
7. + T cell-mediated alloreactivity by inhibiting mature donor T cell expansion and function after bone marrow transplantation
8. HSV-TK gene transfer into donor lymphocytes for control of allogeneic graft-versus-leukemia
9. Altered T-cell receptor + CD28-mediated signaling and blocked cell cycle progression in interleukin 10 and transforming growth factor-β-treated alloreactive T cells that do not induce graft-versus-host disease
10. Transient control of a virus-induced immunopathology by genetic immunosuppression
11. Increased transplant-related morbidity and mortality in CMV-seropositive patients despite highly effective prevention of CMV disease after allogeneic T-cell-depleted stem cell transplantation
12. Hematopoietic stemcell transplantation for the treatment of severe combined immunodeficiency
13. A phase II trial of partially incompatible bone marrow transplantation for high-risk acute lymphoblastic leukaemia in children: Prevention of graft rejection with anti-LFA-1 and anti-CD 2 antibodies
14. Specific elimination of alloreactive T cells by an anti-interleukin-2 receptor β chain-specific immunotoxin
15. Donor T lymphocytes infusion following ex vivo depletion of donor anti-host reactivity by a specific anti-interleukin-2 receptor p55 chain immunotoxin
16. Attenuation of graft-versus-host disease and graft rejection by ex vivo immunotoxin elimination of alloreactive T cells in an H- 2 haplotype disparate mouse combination
17. Costimulatory regulation of T cell function
18. Suicide gene therapy of graft-versus-host disease: Immune reconstitution with transplanted mature T-cells
19. Prevention of graft-versus-host disease in mice using a suicide gene expressed in T lymphocytes
20. Immunological defects after suicide gene therapy of experimental graft-versus-host disease
21. Preservation of graft-versus-infection effects after suicide gene therapy for prevention of graft-versus-host disease
22. Human alloantigen-specific anergic cells induced by a combination of CTLA-Ig and CsA maintain anti-leukemia and anti-viral cytotoxic responses
23. Alloantigen-induced human lymphocytes rendered nonresponsive by a combination of anti-CD80 monoclonal antibodies and cyclosporin-A mixed lymphocyte reaction in vitro
24. The expanding B7 superfamily: Increasing complexity in costimulatory signals regulating T cell function
25. Distinct T cell populations distinguish chronic myeloid leukaemia cells from lymphocytes in the same individual: A model for separating GVHD from GVL reactions
26. B7/CD28-dependent and -independent induction of CD 40 ligand expression
27. Protection from lethal murine graft-versus-host disease without compromise of alloengraftment using transgenic donor T cells expressing a thymidine kinase suicide gene
28. Antibody to the ligand of CD40, gp39, blocks the occurrence of the acute and chronic forms of graft-versus-host disease
29. A phase-I study of an anti-CD25 ricin A-chain immunotoxin (RFT5-SMPT-dgA) in patients with refractory Hodgkin's lymphoma
30. Immunotoxins constructed with anti-CD25 monoclonal antibodies and deglycosylated ricin A-chain have potent anti-tumour effects against human Hodgkin cells in vitro and solid Hodgkin tumours in mice
31. Cytotoxic T-lymphocyte (CTL) response against acute or chronic myeloid leukemia
32. Efficient depletion of alloreactive donor T lymphocytes based on expression of two activation-induced antigens (CD25 and CD69)
33. Bone marrow transplantation (BMT) in Europe for primary immunodeficiencies other than severe combined immunodeficiency: A report from the European Group for BMT and the European Group for Immunodeficiency
34. Effective depletion of alloreactive lymphocytes from peripheral blood mononuclear cell preparations
35. Molecular mechanism for ganciclovir resistance in human T lymphocytes transduced with retroviral vectors carrying the herpes simplex virus thymidine kinase gene
36. Human minor histocompatibility antigens: New concepts for marrow transplantation and adoptive immunotherapy
37. Complete blockade of B7 family-mediated costimulation is necessary to induce human alloantigen-specific anergy: A method to ameliorate graft-versus-host disease and extend the donor pool
38. + T cells
39. + T-cell subset inhibits antigen-specific T-cell responses and prevents colitis
40. Transplantation of anergic histoincompatible bone marrow allografts
41. Long-term immune reconstitution and outcome after HLA-nonidentical T-cell-depleted bone marrow transplantation for severe combined immunodeficiency: A European retrospective study of 116 patients
42. Bone marrow transplants from unrelated donors for patients with chronic myeloid leukemia
43. Hematopoietic stem cell transplants from unrelated donors
44. Inhibition of graft-versus-host disease. Use of a T cell-controlled suicide gene
45. Use of partially mismatched related donors extends access to allogeneic marrow transplant
46. Adenovirus infections in hematopoietic stem cell transplant recipients
47. Bone marrow transplantation from genetically HLA-nonidentical donors in children with fatal inherited disorders excluding severe combined immunodeficiencies: Use of two monoclonal antibodies to prevent graft rejection
48. IL-10 directly acts on T cells by specifically altering the CD28 co-stimulation pathway
49. Analysis of 462 transplantations from unrelated donors facilitated by the National Marrow Donor Program
50. CTLA4-Ig and anti-CD 40 ligand prevent renal allograft rejection in primates
51. Selective removal of alloreactive cells from haematopoietic stem cell grafts: Graft engineering for GVHD prophylaxis
52. Selective inhibition of the canine mixed lymphocyte response by HLA-DR and DP-reactive monoclonal antibodies
53. Enhancement of bone marrow allografts from nude mice into mismatched recipients by T cells void of graft versus host activity
54. Long term acceptance of skin and cardiac allografts after blocking CD 40 and CD28 pathways
55. Anergic T cells as suppressor cells in vitro
56. + T-lymphocyte regeneration after intensive chemotherapy
57. Factors influencing the outcome of bone marrow transplants using unrelated donors
58. Viral infections in children undergoing hematopoietic stem cell Transplantation
59. Susceptibility of proliferating cytolytic T lymphocytes to 33258 Hoechst-modified BUdR and light treatment: Quantitation of the residual precursor cells by limiting dilution analysis
60. Specific depletion of alloreactive T cells in HLA-identical siblings: A method for separating graft-versus-host and graft-versus-leukaemia reactions
61. Specific depletion of alloreactivity against haplotype mismatched related individuals by a recombinant immunotoxin: A new approach to graft-versus-host disease prophylaxis in haploidentical bone marrow transplantation
62. Depletion of alloreactive T cells by a specific anti-interleukin- 2 receptor p55 chain immunotoxin does not impair in vitro antileukemia and antiviral activity
63. A 39-kDa protein on activated helper T cells binds CD 40 and transduces the signal for cognate activation of B cells
64. Activated T cells induce expression of B7/BB1 on normal or leukemic B cells through a CD40-dependent signal
65. Bone marrow transplantation across HLA barriers by increasing the number of transplanted cells
66. Use of gene-modified virus-specific T lymphocytes to control Epstein-Barr-virus-related lymphoproliferation
67. It takes more than two to tango
68. The molecular basis of allorecognition
69. Failure of anti-Ia monoclonal antibody to abrogate transfusion-induced sensitization and prevent marrow graft rejection in DLA-identical canine littermates
70. Quantifying the frequency of alloreactive T cells in vivo: New answers to an old question
71. Administration of herpes simplex-thymidine kinase-expressing donor T cells with a T-cell-depleted allogeneic marrow graft
72. Drug-induced in vitro tolerance to allogeneic antigens. 1. Establishment of a tolerance induction system in a fully allogeneic murine combination
73. Drug-induced in vitro tolerance to allogeneic antigens: II. Further analysis of in vitro-tolerized spleen cells in a fully allogeneic murine combination
74. Synergy between cyclosporin A and a monoclonal antibody to B7 in blocking alloantigen-induced T-cell activation
75. The combination of anti-B7 monoclonal antibody and cyclosporin A induces alloantigen-specific anergy during a primary mixed lymphocyte reaction
76. Reconstitution of cellular immmunity against cytomegalovirus in recipients of allogeneic bone marrow by transfer of T-cell clones from the donor
77. MHC and alloreactivity
78. Infections in adults undergoing unrelated donor bone marrow transplantation
79. 1
80. Specificity of allogeneic cell recognition by human lymphocytes in vitro